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Photoprovocation in Cutaneous Lupus
Erythematosus: A Multicenter Study Evaluating
a Standardized Protocol
Annegret Kuhn1,11, Anna Wozniacka2, Jacek C. Szepietowski3, Regine Gla¨ser4, Percy Lehmann5,
Merle Haust6, Anna Sysa-Jedrzejowska2, Adam Reich3, Vilija Oke7,12, Rainer Hu¨gel4, Cesar Calderon8,
Dick E. de Vries9 and Filippa Nyberg10,12
Photosensitivity is an important and distinguishing sign in various subtypes of cutaneous lupus erythematosus
(CLE); however, it remains poorly defined. The purpose of this study was to evaluate whether standardized
photoprovocation is a reproducible method to assess photosensitivity in subjects with CLE. A total of 47 subjects
with CLE (subacute cutaneous lupus erythematosus (SCLE), n¼ 14; discoid lupus erythematosus (DLE), n¼ 20;
lupus erythematosus tumidus (LET), n¼ 13) and 13 healthy volunteers underwent photoprovocation at seven
European sites. Of these, 22 (47%) subjects (57% SCLE, 35% DLE, and 54% LET) and none of the
healthy volunteers developed photoprovoked lesions according to clinical analysis. Of these 22 subjects,
19 (86%) developed lesions that were histopathologically confirmed as specific for lupus erythematosus (LE). In CLE
subjects who developed UV-induced lesions, 86% had Fitzpatrick’s phototypes I or II, and the mean
minimal erythema dose (MED) was significantly lower compared with subjects without UV-induced lesions
(P¼ 0.004). No significant differences in photoprovocation results were observed between study sites.
Safety parameters showed no clinically meaningful differences between CLE subjects and healthy volunteers
after photoprovocation. In conclusion, a standardized, safe, and reproducible protocol for photoprovocation using
UVA and UVB radiation induced skin lesions in approximately half of all CLE subjects and showed comparable
results across multiple sites. This method may therefore be used for future diagnostic testing and clinical trials.
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INTRODUCTION
Lupus erythematosus (LE) is a heterogeneous autoimmune
disease characterized by a broad range of cutaneous and
systemic manifestations. The expression of skin lesions in LE
shows great variety and has consequently led to the practice
of identifying different subtypes of cutaneous lupus erythe-
matosus (CLE), such as acute CLE, subacute CLE (SCLE), chronic
CLE, and intermittent CLE (Gilliam and Sontheimer, 1981;
Kuhn and Ruzicka, 2005). Because the cutaneous manifesta-
tions of the various disease subtypes are found predominantly
in sun-exposed skin, such as the malar eminences, V-area of
the neck, and extensor areas of the arms, photosensitivity
has long been known to be a pathogenetic factor of LE
(Pusey, 1915; Macleod, 1924). Early clinical studies of
photoprovocation showed that skin lesions can be experi-
mentally induced by UV irradiation; however, the clinical
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phototesting experiments had deficiencies in that either only
a very limited number of LE subjects had been tested or that
UVA irradiation was insufficient to induce lesions (Pusey,
1915; Epstein et al., 1965; Cripps and Rankin, 1973; van
Weelden et al., 1989; Lee and Farris, 1999). In 1986,
Lehmann et al. (1986) developed a phototesting protocol and
determined that the action spectrum of LE reaches into the
long wave UVA region. However, these previous studies are
limited by their single-center design, convenience sampling,
and noncomparable testing procedures at different sites,
resulting in a wide variability of reported photosensitivity and
positive phototesting reactions observed with each subtype,
sample population, and specific phototesting method
(Kuhn and Beissert, 2005; Kuhn et al., 2010).
Although photosensitivity is an important and character-
istic sign in LE, it remains poorly defined. Arguments have
been raised in favor of establishing a more quantifiable
definition of photosensitivity (Nived et al., 1993; Doria et al.,
1996) than that provided by the American College of
Rheumatology as one of the 11 revised criteria used to
classify patients with systemic LE—‘‘skin rash as a result of
unusual reaction to sunlight, by patient history or physician
observation’’ (Tan et al., 1982). One such argument is that
this definition is too broad and also fits other photoderma-
toses such as polymorphous light eruption, which is also
overrepresented in subjects with LE (Nyberg et al., 1997).
Therefore, there is a need for a generally accepted photo-
provocation procedure –e.g., optimal location and size of the
test site; UV irradiation source and dosage; evaluation period
and methods (Lee and Farris, 1999; Kuhn et al., 2001b).
In a formal attempt to reach a standard definition of photo-
sensitivity in subjects with CLE, we conducted a multicenter
study in subjects with different disease subtypes and in
healthy volunteers. We primarily assessed the possibility of
evaluating skin lesion induction with a uniform, standardized
protocol for photoprovocation. This manuscript describes
the demographics and disease characteristics of our study
population and their overall photoprovocation and safety
results. Moreover, we discuss whether photoprovocation
under standardized conditions is a reproducible method to
evaluate photosensitivity in CLE and to assess parameters
potentially influencing the phototesting results in different
subtypes and between various study sites.
RESULTS
Screening and baseline (day 1)
Demographics and disease characteristics. A total of 60
subjects (47 CLE subjects and 13 healthy volunteers)
were enrolled from October 2005 to May 2006 at seven
European sites (in Germany, Scotland, Sweden, and Poland).
All subjects were Caucasian, and 34 of 47 (72%) CLE subjects
and 7 of 13 (54%) healthy volunteers were female (P¼0.312;
Table 1).
At day 1, 39 (79%) of CLE subjects were positive for
antinuclear antibodies (ANA), and only 3 (6%) were positive
for anti-double-stranded DNA (anti-dsDNA) antibodies. The
proportions of CLE subjects seropositive for ANA and anti-
dsDNA antibodies were higher among SCLE subjects (93 and
14%) and discoid lupus erythematosus (DLE) subjects (80 and
5%) than in lupus erythematosus tumidus (LET) subjects
(62 and 0%). At day 1, no healthy volunteer was seropositive
for antibodies to Ro/SSA or La/SSB; 14 (30%) and 6 (13%) of
CLE subjects were seropositive for antibodies to Ro/SSA and/
or La/SSB, respectively. More subjects in the SCLE and DLE
subtypes were seropositive for antibodies to Ro/SSA (SCLE:
71%, DLE: 21%) than to La/SSB (SCLE: 36%, DLE: 5%), and
no LET subject was seropositive. There were no differences of
clinical importance among any groups in the blood chemistry
and hematology values and vital signs at screening.
Threshold doses
No statistically significant threshold testing differences
were found in immediate pigment darkening (IPD; the lowest
dose causing transient brownish-gray coloration of the skin
immediately after irradiation), minimal erythema dose (MED;
minimal dose causing perceptible erythema evaluated
24 hours after irradiation), or minimal tanning dose (MTD;
the lowest dose causing persistent pigment darkening
evaluated 24 hours after irradiation) values between CLE
subjects and healthy volunteers (Table 2); and no clinically
meaningful differences were found across study centers (data
not shown). No significant differences were observed in IPD
between CLE subjects who had positive versus negative
photoprovocation results (Figure 1a), although photoprovo-
cation-positive LET subjects had a significantly lower mean
IPD than photoprovocation-negative LET subjects (P¼0.018;
Table 2). A significantly lower MED was observed in
photoprovocation-positive compared with photoprovoca-
tion-negative CLE subjects (P¼0.004; Figure 1a); this
difference was also evident in the DLE and LET subtypes
(P¼0.015 and 0.012, respectively; Figure 1b). Mean MTD
values did not differ significantly between photoprovocation-
positive and -negative CLE subjects (Figure 1a), although a
significantly lower MTD was observed in photoprovocation-
positive LET subjects than in photoprovocation-negative LET
subjects (P¼0.019; Figure 1c).
Overall photoprovocation results
No healthy volunteer developed skin lesions characteristic
for UV-induced LE. Of 13 healthy volunteers, 5 were assessed
with skin biopsy from photoprovocation sites, and none
showed any histological sign of LE lesions. Of 47 CLE
subjects, 22 (47%) had a positive provocative phototest: 8/14
(57%) SCLE subjects, 7/20 (35%) DLE subjects, and 7/13
(54%) LET subjects (Table 2). A photograph of a typical
photoprovoked lesion in a subject having a positive photo-
provocation test is shown in Figure 2. LE-specific histopatho-
logical features were observed in the biopsy samples of fully
developed lesions in 19 (86%) of these 22 photoprovocation-
positive CLE subjects. Of the three photoprovocation-positive
subjects not having LE-specific lesions, one LET subject and one
SCLE subject were noted as having lichen simplex chronicus,
and the second LET subject as having dermatitis. However, an
acute flare of LE could not be excluded for the second LET
subject. Although these three subjects developed histopatholo-
gically unconfirmed lesions, the clinical presentation of their
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lesions was sufficient for the investigators to consider these
subjects positive responders to photoprovocation.
The times to the onset of positive photoprovocation and to
the determination of a fully developed skin lesion were
variable across CLE subtypes and longest in SCLE subjects
(Table 2 and Figure 1d). Some variability in these times was
observed across study centers, although the differences were
not statistically significant (data not shown).
On average, healthy volunteers were 13 years younger
than photoprovocation-positive CLE subjects (P¼ 0.004) and
9 years younger than photoprovocation-negative CLE sub-
jects (P¼0.047). Skin type I–IV, according to Fitzpatrick’s
phototypes (Fitzpatrick, 1988), was similarly distributed
among photoprovocation-negative CLE subjects and healthy
volunteers (Table 1). However, a higher proportion of photo-
provocation-positive CLE subjects (86%) had skin type I or II
compared with photoprovocation-negative CLE subjects
(52%, P¼0.015) and healthy volunteers (62%, P¼0.116;
Table 1).
Among CLE subjects, the median time from last lesion
flare-up to baseline was nearly twice as long for photo-
provocation-positive than photoprovocation-negative CLE
subjects (9.5 vs. 5 months; Table 1). A significantly higher
percentage of CLE subjects than healthy volunteers had a
history of smoking (83 vs. 46%, P¼ 0.012) and had smoked
for more years on average (27±12 vs. 9±6 years, P¼0.002;
Table 1). Seropositivity for ANA, anti-dsDNA, anti-Ro/SSA,
and anti-La/SSB antibodies did not appear to affect photo-
provocation results.
Treatment with antimalarials and smoking
Of the eight CLE subjects who were taking antimalarials during
the study, two (25%) developed lesions after photoprovocation.
Both of these photoprovocation-positive subjects were smo-
kers, and five (83%) of the six photoprovocation-negative
subjects were also smokers. Of the 39 subjects who were not
taking antimalarials, 20 (51%) developed lesions following
photoprovocation. Of these 20 subjects, 19 (95%) were
smokers. Of the 19 subjects not taking antimalarials who did
not develop lesions, 13 (68%) were smokers. No statistical
differences based on the use of antimalarials could be
calculated because of the small sample size.
Safety
All 13 healthy volunteers completed all procedures sche-
duled through day 11. There were no clinically meaningful
differences in adverse events (AEs) reported following photo-
provocation in photoprovocation-positive and -negative CLE
subjects versus healthy volunteers. No clinically meaningful
differences were observed in the AEs reported across the
Table 1. Summary of demographics, medical history, and disease characteristics1
Photoprovocation+ CLE subjects Photoprovocation CLE subjects
SCLE
(n=8)
DLE
(n=7)
LET
(n=7)
Total
(n=22)
SCLE
(n=6)
DLE
(n=13)
LET
(n=6)
Total
(n=25)
All CLE subjects
(n=47)
Healthy volunteers
(n=13)
Age (years) 55±10 53±8 44±5 51±9 45±15 44±12 55±10 47±12 49±11 38±12
Female 8 (100) 4 (57) 5 (71) 17 (77) 6 (100) 7 (54) 4 (67) 17 (68) 34 (72) 7 (54)
Phototype
I 1 (13) 1 (14) 3 (43) 5 (23) 1 (17) 0 (0) 0 (0) 1 (4) 6 (13) 1 (8)
II 7 (88) 4 (57) 3 (43) 14 (64) 1 (17) 6 (46) 5 (83) 12 (48) 26 (55) 7 (54)
III 0 (0) 2 (29) 1 (14) 3 (14) 3 (50) 6 (46) 1 (17) 10 (40) 13 (28) 4 (31)
IV 0 (0) 0 (0) 0 (0) 0 (0) 1 (17) 1 (8) 0 (0) 2 (8) 2 (4) 1 (8)
History of smoking 7 (88) 7 (100) 7 (100) 21 (96) 3 (50) 10 (77) 5 (83) 18 (72) 39 (83) 6 (46)
Years smoked 25±12 32±9 26±10 28±10 22±20 23±11 31±16 25±14 27±12 9±6
Height (cm) 162±6 165±12 167±6 165±8 166±5 168±9 166±9 167±8 166±8 171±10
Weight (kg) 63±10 64±18 74±19 67±16 70±11 71±11 78±22 73±14 70±15 70±11
Months since last flare
n 7 6 7 20 6 12 6 24 44 —
Median
(interquartile
range)
23 (9, 31) 9 (5, 10) 5 (1, 30) 9.5 (4, 28.5) 4 (3, 9) 7 (4, 13.5) 4.5 (2, 7) 5 (3, 8.5) 7.5 (3, 19.5) —
Abbreviations: CLE, cutaneous lupus erythematosus; DLE, discoid lupus erythematosus; LET, lupus erythematosus tumidus; SCLE, subacute cutaneous lupus
erythematosus.
1Data are presented as mean±SD or n (%) unless otherwise indicated. Total percentages may not sum to 100 due to rounding.
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seven study centers. AEs were reported in all groups, most
frequently by photoprovocation-positive CLE subjects (59%),
followed by photoprovocation-negative CLE subjects (36%)
and then healthy volunteers (31%; Table 3). Most AEs were
negligible and unrelated to phototesting and photoprovoca-
tion, with the exception of the cases of exacerbation of CLE,
i.e., the development of skin lesion(s) outside of the UV-
irradiated area (15%; four photoprovocation-positive and
Table 2. Threshold doses of UV light and overall photoinduction and photoprovocation results—all subjects1,2
Photoprovocation+ CLE subjects Photoprovocation CLE subjects
SCLE
(n=8)
DLE
(n=7)
LET
(n=7)
Total
(n=22)
SCLE
(n=6)
DLE
(n=13)
LET
(n=6)
Total
(n=25)
All CLE subjects
(n=47)
Healthy volunteers
(n=13)
IPD-UVA (J cm–2) 57.5±22.5 37.1±21.4 48.6±10.7 48.2±20.2 53.3±16.3 40.0±11.5 66.7±10.3 49.6±16.5 48.9±18.1 43.1±21.4
MED-UVB (mJ cm–2) 115.6±26.5 85.7±19.7 82.1±18.9 95.5±26.3 129.2±33.2 119.2±27.3 112.5±13.7 120.0±26.0 108.5±27.9 100.4±24.2
1.5 MED-UVB (mJ cm–2) 172.8±39.5 128.5±29.6 122.9±28.5 142.8±39.3 193.7±50 178.8±41.0 168.8±20.5 180.1±39.1 162.8±42.3 152.3±32.0
MTD-UVA ( J cm–2) 70.0±10.7 60.0±11.5 51.4±10.7 60.9±13.1 63.3±8.2 63.1±18.0 76.7±19.7 66.4±17.0 62.7±15.4 58.5±15.2
Subjects with positive
photoprovocation test
8/14 (57) 7/20 (35) 7/13 (54) — 0 0 0 0 22/47 (47) 0
Subjects with biopsy
samples
8 7 7 22 — — — — — 5
LE histopathological
features
7/8 (88) 7/7 (100) 5/7 (71) 19 (86) — — — — — 0
Days to onset of positive
response
9.6±6.0 5.1±7.5 7.7±5.8 7.6±6.4 — — — — — —
7.5 (6, 16) 1 (0, 16) 7 (2, 15) 6 (1, 16)
Days to fully developed
lesion
13.9±5.7 11.0±5.9 10.0±4.4 11.7±5.4 — — — — — —
16 (8.5, 16.5) 9 (6, 16) 9 (8, 15) 9 (8, 16)
Abbreviations: CLE, cutaneous lupus erythematosus; DLE, discoid lupus erythematosus; IPD, immediate pigment darkening; LE, lupus erythematosus;
LET, lupus erythematosus tumidus; MED, minimal erythema dose; MTD, minimal tanning dose; SCLE, subacute cutaneous lupus erythematosus.
1Data presented as mean±SD, n (%), or median (interquartile range). Total percentages may not sum to 100 due to rounding.
2Results are presented only for areas with an occurrence of erythema or pigmentation.
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Figure 1. Threshold testing values and times to onset of positive response and fully developed skin lesions. Mean±SD values from threshold testing (on day 1)
for (a) immediate pigment darkening (IPD), minimal erythema dose (MED), and minimal tanning dose (MTD) in photoprovocation-positive and -negative
cutaneous lupus erythematosus (CLE) subjects and for (b) MED and (c) MTD across CLE subtypes. (d) Times to the onset of positive response (black box-
and-whiskers) and to fully developed skin lesion (white box-and-whiskers) after photoprovocation (on days 2–4) in photoprovocation-positive CLE subjects.
Box-and-whisker plots present the median, interquartile range, and range for each group. DLE, discoid lupus erythematosus; LET, lupus erythematosus tumidus;
SCLE, subacute cutaneous lupus erythematosus. wPo0.01; *Po0.05.
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three photoprovocation-negative CLE subjects). Of these
seven CLE exacerbations, five were confined to one study
center. These exacerbations were transient and either mild or
moderate in severity. In both photoprovocation-positive and
-negative CLE subjects, the severity of AEs was either mild or
moderate. Also of note, the following musculoskeletal and
connective tissue AEs were reported: back pain (one SCLE,
one DLE), arthralgia (one DLE), muscular weakness (one
DLE), and periarthritis (one LET).
One serious AE was reported: a 44-year-old, Caucasian,
male, photoprovocation-positive LET subject with a history of
hypercholesterolemia experienced a mild cardiac palpitation
resulting in hospitalization that was not considered related to
UV irradiation. No subject withdrew from the study because
of an AE. No deaths were associated with this study.
One DLE subject positive for ANA at day 1 had an
increase in ANA titer from 1:160 at week 1 to 1:320 at week
2, to 1:1,280 at week 3, and finally decreased to 1:320 at
week 5. Anti-dsDNA antibody status generally did not
change over time for the three subjects who tested positive
at day 1, and no subject developed seropositivity following
phototesting. No subjects seronegative at day 1 for anti-Ro/
SSA or anti-La/SSB antibodies had become seropositive at
week 5 after photoprovocation. No clinically meaningful
changes from screening were observed in blood chemistry,
hematology, or vital signs between or within photoprovoca-
tion-positive and -negative CLE subjects and healthy volun-
teers or any CLE subtype. However, immunoglobulin (Ig) A
and IgG elevation and decreased lymphocyte count were
reported in one subject each in the DLE subtype.
DISCUSSION
To our knowledge, a multicenter study to evaluate photo-
sensitivity in CLE subjects using a uniform, controlled,
standardized photoprovocation test is previously unreported.
Photoprovoked lesions were observed in almost half (22/47,
47%) of all tested CLE subjects by 4 weeks after UV
irradiation for 3 consecutive days using photoprovocation
with 1 MTD (mean 60.9 J cm–2) of UVA followed by 1.5
MEDs (mean 142.8mJ cm–2) of UVB. No clinically mean-
ingful difference in photoprovocation results was found
across the seven study centers. Previous studies showed an
overall positive photoprovocation rate of 33–93% using
slightly different protocols (Lehmann et al., 1990; Hasan
et al., 1997; Walchner et al., 1997; Leenutaphong and
Boonchai, 1999; Kuhn et al., 2001b; Sanders et al., 2003).
Our results are at the lower end of this range, possibly
because of the inclusion of subjects taking antimalarials, the
low dose of UVA irradiation administered, and the use of
only a combination of UVA and UVB irradiation.
The MED was significantly lower for DLE and LET subjects
who developed lesions in response to photoprovocation than
for those who did not. This suggests that CLE subjects of these
subtypes who develop photoprovoked lesions have a lower
MED and are therefore more sensitive to UV light in general.
In contrast to previous findings that LET is the most
photosensitive subtype (Kuhn et al., 2001a), SCLE subjects
were the subtype with the highest percentage of photopro-
vocation-positive subjects in our study, although the SCLE
subtype had the highest MED. This suggests that the MED is
not the only factor that determines photoprovocation. There
may be underlying pathogenetic factors, such as the HLA-
type, that play a role in lesion development. No similar trend
was evident in the MTD or the IPD, indicating that they are
possibly of lesser importance than the MED in defining
photosensitivity. Two of eight subjects treated with anti-
malarials developed photoprovoked CLE, suggesting that
these subjects may be to some extent protected by their
treatment, as reported in previous studies (Wozniacka et al.,
2002, 2007).
On average, approximately 8 days elapsed before the first
appearance of a developing lesion and 12 days before the
appearance of a fully developed lesion. This is in accordance
with previous reports on phototesting in the literature (Kuhn
et al., 2001b). This 1- to 2-week delay observed in the
appearance of induced lesions in the subjects enrolled in this
study corroborates previous criticisms that the revised 1982
American College of Rheumatology criterion on photosensi-
tivity, defined as ‘‘skin rash as a result of unusual reaction to
sunlight, by patient history or physician observation’’ (Tan
et al., 1982), is unspecific for the diagnosis of systemic LE if
evaluated by patient history (Albrecht et al., 2004) because
subjects may have difficulty linking sun exposure to their
disease (Kuhn et al., 2001b; Kuhn and Beissert, 2005; Kuhn
et al., 2010). In contrast, blinded histopathological analysis
of lesional skin biopsy specimens was able to confirm
Figure 2. Clinical image of a typical photoprovoked lesion in a
photoprovocation-positive cutaneous lupus erythematosus (CLE) subject.
This photograph was taken on day 18. Bar¼1mm.
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LE-specific features in 19 of 22 photoprovocation-positive
CLE subjects in our study, suggesting that photoprovocation
can be used as a valuable diagnostic tool if verified by
histology; details on this analysis will be reported in a separate
publication. Previously reported observations that LE-specific
histological features were seen early after photoprovocation in
subjects who developed clinically typical photoprovoked CLE
underscore the possibility in differentiating these specimens
from other photodermatoses such as polymorphous light
eruption (Nyberg et al., 1999). However, our results point
out the importance of repeated biopsies, as the histopathology
was unspecific at this early stage in 3 of 22 subjects, and the
determination of fully developed LE lesion rested on clinical
examination, as per protocol we did not follow-up with
repeated biopsies to confirm the clinical diagnosis.
Additionally, a significantly higher percentage (86%) of
photoprovocation-positive CLE subjects had Fitzpatrick’s
phototype I or II, which corresponded to a lower MED, com-
pared with photoprovocation-negative CLE subjects (52%).
Because CLE subjects who had a more UV-sensitive photo-
type and a lower MED were more likely to develop photo-
provoked lesions in our study, we hypothesize that phototype
and MED may be possible predictors of photosensitivity
in CLE.
In our sample study population, CLE subjects were
generally older compared with healthy volunteers, although
this difference did not likely affect the photoprovocation
outcome. In addition, a higher percentage of CLE subjects
were smokers compared with healthy volunteers; this same
trend was observed in a prospective multicenter case–control
study conducted in France (Boeckler et al., 2009). Moreover,
a higher percentage of photoprovocation-positive than
-negative CLE subjects had a history of smoking (96 vs.
72% subjects). It may be that CLE subjects who are smokers
have higher disease activity compared with nonsmoking CLE
subjects (Boeckler et al., 2009; Kreuter et al., 2009).
A significantly higher percentage of CLE subjects than
healthy volunteers were positive for ANA. Only CLE
subjects were positive for antibodies to Ro/SSA or La/SSB.
Seropositivity for ANA and antibodies against Ro/SSA and
La/SSB was distributed similarly for photoprovocation-
positive and -negative CLE subjects. No group differences
were observed for anti-dsDNA antibodies, as only three CLE
subjects were positive for these antibodies. Seropositivity
for these antibodies alone did not appear to influence a
subject’s photoprovocation result, and the administration of
the photoprovocation test generally did not appear to induce
the development of any of these autoantibodies. However,
Table 3. Summary of AEs that occurred in at least five total subjects1
Photoprovocation+ CLE subjects Photoprovocation CLE subjects
SCLE
(n=8)
DLE
(n=7)
LET
(n=7)
Total
(n=22)
SCLE
(n=6)
DLE
(n=13)
LET
(n=6)
Total
(n=25)
All CLE subjects
(n=47)
Healthy volunteers
(n=13)
Subjects with one or more AEs 4 (50) 5 (71) 4 (57) 13 (59) 2 (33) 6 (46) 1 (17) 9 (36) 22 (47) 4 (31)
General disorders and administration
site conditions
2 (25) 3 (43) 0 5 (23) 2 (33) 2 (15) 0 4 (16) 9 (19) 3 (23)
Application site pain 1 (13) 2 (29) 0 3 (14) 0 0 0 0 3 (6) 2 (15)
Application site irritation 0 2 (29) 0 2 (9) 1 (17) 2 (15) 0 3 (12) 5 (11) 1 (8)
Application site pruritus 0 2 (29) 0 2 (9) 1 (17) 2 (15) 0 3 (12) 5 (11) 2 (15)
Infections and infestations 1 (13) 2 (29) 2 (29) 5 (23) 1 (17) 3 (23) 0 4 (16) 9 (19) 1 (8)
Skin and subcutaneous tissue disorders 1 (13) 3 (43) 1 (14) 5 (23) 2 (33) 2 (15) 0 4 (16) 9 (19) 0
CLE (outside of the UV-irradiated area) 1 (13) 3 (43) 0 4 (18) 1 (17) 2 (15) 0 3 (12) 7 (15) 0
Laboratory investigations 1 (13)2 3 (43)3 0 4 (18) 0 1 (8)2 0 1 (4) 5 (11) 0
Musculoskeletal and connective tissue
disorders
1 (13) 2 (29) 1 (14) 4 (18) 0 1 (8) 0 1 (4) 5 (11) 0
Nervous system disorders 1 (13) 2 (29) 1 (14) 4 (18) 1 (17) 1 (8) 0 2 (8) 6 (13) 3 (23)
Headache 1 (13) 2 (29) 1 (14) 4 (18) 1 (17) 1 (8) 0 2 (8) 6 (13) 3 (23)
Abbreviations: AE, adverse event; CLE, cutaneous lupus erythematosus; DLE, discoid lupus erythematosus; LET, lupus erythematosus tumidus;
SCLE, subacute cutaneous lupus erythematosus.
1Data presented as n (%). Total percentages may not sum to 100 due to rounding.
2Antinuclear antibody (ANA) increased.
3Blood immunoglobulin (Ig) A or IgG increased, anti-double-stranded DNA (anti-dsDNA) antibody positive, lymphocyte count decreased.
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as expected, positivity for antibodies to Ro/SSA and La/SSB
was most common in the SCLE subtype, which was the group
with the highest percentage of photoprovocation-positive
patients.
Local and systemic side effects from the phototesting
procedure were rare in this study population, with the most
commonly reported being administration-site reactions and
headache. No clinically meaningful differences in safety
events were observed between CLE subjects and healthy
volunteers or across study centers. Most reported AEs were
negligible, except for the seven cases of mild exacerbation of
CLE skin lesions outside of the UV-irradiated area. Events
such as decreased lymphocyte count, IgG elevation, and
possibly musculoskeletal and connective tissue symptoms
were each reported only by one or two subjects and were
therefore not clinically significant. However, inductions of
organ involvement, such as lupus nephritis, have been
reported to develop in systemic LE subjects after extensive
sun exposure (Stern and Docken, 1986; Schmidt et al., 2007)
and should be carefully monitored in future phototesting
studies.
Considering that the severity of CLE is variable, and that
this study was conducted during winter, a generally accepted
waning disease period, the need for consensus among the
study sites in reporting CLE exacerbations outside of the UV-
irradiated area is evident. We conducted a retrospective
review of study files on the seven subjects with exacerba-
tions, revealing that the AEs in four of them were related to
small clinical changes on pre-existing lesions. Overall, the
AEs in these four subjects (three DLE and one SCLE) were
transient, mild in intensity, and did not require the use of
medications in all but one subject. The other three subjects
(two DLE and one SCLE) developed new CLE lesions outside
of the UV-irradiated area. In summary, it is plausible to
speculate that the latter observations reported as CLE exacer-
bation may have been a result of the natural fluctuations in
disease activity. Photoprovocation was in general well
tolerated and without significant clinical concerns. However,
conclusions related to the reported disease exacerbations at
this point would be equivocal. Increasing the sample size and
the inclusion of a control group to account for the natural
fluctuation in disease activity would increase the robustness
of safety data in future photoprovocation studies.
Our study results suggest that a uniform, controlled
photoprovocation test is a reproducible method to evaluate
photosensitivity in CLE subjects showing similar results
between sites for certain parameters. Using a standard
phototesting protocol with standard UVA and UVB irradia-
tion equipment, we were able to induce lesions in approxi-
mately half of all CLE subjects across multiple study centers.
Most CLE subjects who responded positively to the photo-
provocation developed lesions histopathologically proven to
exhibit LE characteristics, suggesting that photoprovocation
can be used as a diagnostic test for CLE and as a model for
research on the disease pathophysiology. However, histo-
pathology is not likely to be specific enough at an early stage
of the disease to discriminate between subtype according to
our results and previous attempts to describe histopathological
criteria (Lipsker, 2010). In our sample population, CLE subjects
with more UV-sensitive skin as defined by Fitzpatrick’s
phototype and lower MED were more likely to respond to
photoprovocation—this finding should be considered in future
clinical trials to evaluate the effect of a local or systemic
treatment on CLE subjects. Recently, standardized phototest-
ing was used in a randomized, vehicle-controlled, double-
blind study showing that the use of broad-spectrum sunscreen
can prevent skin lesions in photosensitive patients with
different subtypes of CLE (Kuhn et al., 2011). Our results and
this recent finding combined highlight the importance of
using photoprotection in CLE subjects who are prone to
developing UV-induced lesions.
MATERIALS AND METHODS
Study subjects were patients (age 18–70 years) diagnosed with
SCLE, DLE, or LET or healthy volunteers (age X18 years). The
diagnosis of the different subtypes of CLE was based on clinical and
histopathological findings according to the Gilliam and Sontheimer
Classification (Gilliam and Sontheimer, 1981) and the Du¨sseldorf
Classification 2004 (Kuhn and Ruzicka, 2005).
Major exclusion criteria were a history of other photodermatoses
(except for polymorphous light eruption); direct exposure to UV light
on the tested areas within 2 weeks before entering the study; solar
simulator exposure on the back within 12 weeks of entering the
study; use of immunosuppressive or cytotoxic agents other than
antimalarials; and any medical condition that, in the investigator’s
opinion, placed the subject at undue risk, or made it unlikely that
follow-up measurements could be obtained. The use of photo-
sensitizing drugs and nonsteroidal anti-inflammatory drugs was
prohibited during the trial.
A detailed medical history including ethnicity, history of
smoking, and skin phototype according to Fitzpatrick (Fitzpatrick,
1988) was obtained.
Study design
This was a longitudinal study to assess the possibility of inducing
skin lesions in subjects with CLE using a uniform, controlled,
conventional photoprovocation test at multiple study sites.
Following a 2-week screening period, subjects underwent
threshold testing on six 4.5 cm2 areas of the lower back each for
UVA and UVB irradiation on day 1. UVA was gradually irradiated at
10, 20, 40, 60, 80, and 100 J cm–2 using a high-pressure metal halide
lamp (323–436 nm, Sellamed 3000, Sellas, Medizinische Gera¨te,
Gevelsberg, Germany), whereas UVB was irradiated at 25, 50, 75,
100, 125, and 150mJ cm–2 using a UV-801 unit lamp with
fluorescent bulbs (285–350 nm, Philips TL 20 W/12, Waldmann,
Villingen/Schwenningen, Germany). IPD was evaluated within
60 seconds after UVA irradiation. On day 2 (24 hours after day 1
threshold testing), the MTD for UVA and the MED for UVB were
evaluated. The dose intensities used for UVA and UVB irradiation for
photoprovocation were customized for each subject by determining
his or her individual MTD and MED, respectively, from threshold
testing. Thereafter, 5 7 cm areas of uninvolved skin on the upper
back were irradiated daily for 3 consecutive days with the MTD for
UVA followed by 1.5 MEDs of UVB. All subjects were prohibited
from exposure to direct UV radiation and the use of sunscreen on the
tested areas.
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Subjects were clinically examined for the diagnosis of positive
photoprovocation response (based on the development of a lesion
on photoprovoked skin areas) and the time from the first
photoprovocation dose to the development of the skin lesion on
days 2, 3, 4, 5, 8, 11, 18, 25, and 32. Skin biopsies from the photo-
provoked site in CLE subjects and healthy volunteers were assessed
by a histopathologist who was blinded to photoprovocation outcome
and subject group to explore whether the photoprovoked lesions
had LE-specific features. A detailed report of the histopathological
assessment will be published separately. Safety parameters were
evaluated for all subjects by monitoring AEs, serious AEs; the
development of ANA and antibodies to dsDNA, Ro/SSA, and
La/SSB; chemistry and hematology values; and vital signs following
phototesting.
The protocol was designed according to the Declaration of
Helsinki Principles. The ethics committee of Witten/Herdecke
University, University of Kiel, and University of Du¨sseldorf,
Germany; Ninewells Hospital and Medical School, UK; Regional
Ethics Committee in Stockholm, Sweden; and Wroclaw Medical
University, Poland, approved all described studies. All subjects
provided informed written consent.
Statistical analysis
Descriptive statistics were used to summarize the threshold doses of
MED, IPD, and MTD and the incidence and time of the onset of each
positive photoprovocation test. Results are summarized for photo-
provocation-positive CLE subjects (i.e., subjects who developed
positive reactions/pathological skin lesions at the site of testing
within 4 weeks from the last irradiation dose), photoprovocation-
negative CLE subjects (i.e., subjects who did not develop positive
reactions/pathological skin lesions at the site of testing within 4
weeks from the last irradiation dose), each photoprovocation-
positive and -negative CLE subtype, and healthy volunteers. Within
each subject group, these results were analyzed by study center to
determine the uniformity of the phototesting procedure. Mean, SD,
median, and range were used to summarize continuous variables.
Frequency and proportion were used to summarize categorical
variables.
Approximately 50 total subjects were planned for enrollment
in the study: 10 healthy volunteers as controls and 40 subjects
with CLE. Any subject lost to follow-up or who withdrew
consent before the 4-week time frame was replaced to meet the
target enrollment of 30 subjects who tested positive for photo-
provocation.
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